Prevymis (letermovir) is prescribed to prevent cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic stem cell transplant (SCT) [1].
How is Prevymis administered?
Prevymis is available as an oral tablet or an intravenous (IV) solution [1]. The recommended dose is 480 mg taken orally twice a day for the first 13 weeks after transplant, followed by 960 mg taken orally once a day for up to 24 weeks. For IV administration, the recommended dose is 480 mg infused over one hour twice a day for the first 13 weeks post-transplant, followed by 960 mg infused over one hour once a day for up to 24 weeks [1]. Dosing adjustments may be necessary for patients with moderate to severe renal impairment [1].
What are the potential side effects of Prevymis?
Common side effects associated with Prevymis include diarrhea, nausea, vomiting, abdominal pain, fatigue, headache, cough, and decreased potassium levels [1]. Serious side effects can include hypersensitivity reactions, including rash and urticaria, and potential drug interactions [1].
How does Prevymis work to prevent CMV?
Prevymis is a cytomegalovirus inhibitor that works by targeting the pUL56 protein in the CMV viral terminase complex. This inhibition prevents the processing of viral DNA, thereby blocking viral replication [1].
What is the recommended duration of Prevymis treatment?
The recommended duration of Prevymis treatment is up to 24 weeks after an allogeneic stem cell transplant. This includes an initial 13-week period at a higher dose, followed by an extended period at a maintenance dose [1].
Are there any drug interactions with Prevymis?
Prevymis can interact with certain medications, including strong CYP3A inhibitors and inducers, as well as P-glycoprotein (P-gp) inhibitors and inducers. Co-administration with certain drugs may require dose adjustments or avoidance [1]. For example, it should not be taken with rifampin, which can significantly decrease Prevymis levels [1].
What are the contraindications for Prevymis?
Prevymis is contraindicated in patients who are taking strong CYP3A inducers, such as rifampin, because these can substantially lower Prevymis plasma concentrations [1].
Where can I find the full prescribing information for Prevymis?
The full prescribing information for Prevymis, including detailed dosing, administration, warnings, precautions, and adverse reactions, is available from the manufacturer and through resources like DrugPatentWatch.com [1].